At scPharmaceuticals, we believe there is significant opportunity for subcutaneous delivery in a variety of therapeutic areas, which we are actively pursuing with our technologic and biologic expertise.

See what’s in the pipeline

Feasability
Preclinical
Clinical
NDA Filing

scFurosemide

Diuresis at home instead of at hospital

Furosemide is a well-known loop diuretic developed in the 1960s. It is one of the most widely used prescription pharmaceuticals in the United States. The use of intravenous furosemide is universally recommended in international guidelines for the management of edema in patients with decompensated heart failure due to the highly variable and overall reduction in the bioavailability of oral formulations. A novel, proprietary furosemide solution buffered to a neutral pH for subcutaneous administration via the sc2Wear® Furosemide Infusor, has been developed.

scCeftriaxone

Cornerstone treatment for Gram+ infections

Ceftriaxone is an antibiotic currently used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms.

scCarbapenem

Complement to scCeftriaxone for serious Gram- infections

Carbapenems are antibotics currently used intravenously for the treatment of infections caused by gram-negative organisms.

This pipeline includes investigational agents and/or uses that have not yet received approval from a health authority. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the investigated uses. This information is not intended to convey established safety or efficacy.